8-K: Nuwellis Q3 Revenue Dips, Focuses on US Growth

Nuwellis, Inc. reported third quarter 2025 financial results with total revenue of $2.2 million, a 6% year-over-year decrease, while advancing its U.S.-focused cardiorenal growth strategy.

Summary

• Total revenue for the third quarter of 2025 was $2.2 million, a 6% decrease compared to $2.4 million in the prior year quarter.
• On a pro-forma basis, revenue grew approximately 7% year-over-year, excluding one-time SeaStar medical revenue of $0.2 million in Q3 2024 and a $0.1 million decrease in international revenue.
• Sequentially, revenue increased 29% from the second quarter of 2025, driven by higher consumable utilization and increased U.S. console placements.
• Gross margin decreased to 65.2% in Q3 2025 from 70.0% in Q3 2024, attributed to unfavorable manufacturing utilization.
• Operating expenses rose 30% year-over-year to $4.1 million, reflecting increased investment in the U.S. sales force and engineering/quality systems.
• Operating loss widened to $2.7 million in Q3 2025, compared to $1.5 million in the prior year quarter.
• The company reported a net income of $468,000 for Q3 2025, primarily due to a $3.161 million change in the fair value of warrant liabilities.
• Nuwellis ended the quarter with $3.1 million in cash and cash equivalents and remains debt-free.
• The company raised $1.9 million through its At-The-Market (ATM) facility during the quarter.

Sentiment

Score: 4

Explanation: While there are strategic positives like new product launches, expansion into outpatient settings, and a focused U.S. market strategy, the core financial metrics (revenue decline, gross margin compression, increased operating loss, and cash burn) indicate a challenging quarter. The reported net income is misleading due to a non-cash gain from warrant liabilities. The company is executing on strategic shifts but faces significant financial headwinds.

Positives

• Pro-forma revenue grew approximately 7% year-over-year, adjusting for specific one-time items and international wind-down.
• Sequential revenue increased 29% from the second quarter, driven by higher consumable utilization and increased U.S. console placements.
• All customer categories, including critical care, heart failure, and pediatrics, achieved year-over-year growth in circuit sales.
• Successfully delivered the first Aquadex therapies in a hospital-based outpatient setting under a new CMS code, expanding access.
• Launched a new 24-hour circuit and dual-lumen extended-length catheter in the U.S., enhancing provider flexibility.
• Accelerated pediatric product development through an NIH-funded collaboration for the Vivian pediatric CRRT system and a newly issued U.S. patent.
• Initiated manufacturing transition to KDI Precision Manufacturing and began exiting international operations to focus on U.S. market growth.
• The company remains debt-free.

Negatives

• Total revenue decreased 6% year-over-year to $2.2 million.
• Gross margin declined to 65.2% from 70.0% in the prior year quarter, impacted by unfavorable manufacturing utilization.
• Operating expenses increased 30% year-over-year to $4.1 million.
• Operating loss widened to $2.7 million from $1.5 million in the prior year quarter.
• Cash and cash equivalents decreased to $3.1 million as of September 30, 2025, from $5.1 million at December 31, 2024.
• The reported net income for Q3 2025 is primarily driven by a non-cash gain from the change in fair value of warrant liabilities, masking an underlying operational loss.

Risks

• Ability to execute on the commercialization strategy.
• Possibility of being unable to raise sufficient funds necessary for anticipated operations.
• Risks associated with post-market clinical data collection activities.
• Uncertainty regarding the benefits of products to patients.
• Risks related to product development and commercialization efforts.
• Ability to increase market and physician acceptance of products.
• Potential competitive product offerings.
• Challenges in intellectual property protection.
• Ability to integrate acquired businesses and realize anticipated synergies and benefits.
• Other risks and uncertainties described in SEC filings.

Future Outlook

Nuwellis anticipates new market opportunities and continued growth in 2025 and beyond, driven by its focused U.S.-driven business strategy, expansion of Aquadex therapy delivery into new settings, and ongoing pediatric product development, including the Vivian CRRT system.

Management Comments

• "Our third quarter results reflect disciplined execution and meaningful progress toward building a more focused, U.S.-driven business." John Erb, Chairman and Chief Executive Officer.
• "We continue to strengthen our leadership in precision fluid management across critical care, pediatrics, and hospital-based outpatient therapy." John Erb.
• "With the launch of our new 24-hour circuit and successful early hospital-based outpatient treatments, we are expanding how and where Aquadex therapy can be delivered to improve patient outcomes." John Erb.

Industry Context

Nuwellis operates in the medical technology sector, specializing in precision fluid management for cardio-renal conditions. The company's strategic shift to focus on the U.S. market, coupled with the expansion into hospital-based outpatient settings and accelerated pediatric product development (Vivian system), positions it to address specific, growing needs within critical care and nephrology. This strategy aims to optimize resource allocation and capture market share in a competitive medical device landscape by targeting underserved patient populations and new care delivery models.

Stakeholder Impact

• Shareholders: Potential dilution from the ATM facility, continued operating losses may impact share value, but strategic focus on the U.S. market and product innovation could offer long-term value.
• Customers (Healthcare Providers): Enhanced flexibility with new products (24-hour circuit, extended-length catheter) and expanded access to Aquadex therapy through outpatient settings.
• Patients: Improved access to ultrafiltration therapy and accelerated development of pediatric CRRT systems (Vivian) for fragile patients.
• Employees: Increased investment in rebuilding the U.S. sales force suggests potential for new hires in that area, while the exit from international operations might imply changes for international staff.
• Suppliers: Transitioning manufacturing to KDI Precision Manufacturing indicates a change in supplier relationships.

Next Steps

• Continue disciplined execution and building a more focused, U.S.-driven business.
• Strengthen leadership in precision fluid management across critical care, pediatrics, and hospital-based outpatient therapy.
• Expand how and where Aquadex therapy can be delivered to improve patient outcomes, leveraging the new 24-hour circuit and hospital-based outpatient treatments.
• Advance pediatric product development, including the NIH-funded collaboration for the Vivian pediatric CRRT system.
• Complete manufacturing transition to KDI Precision Manufacturing and exit international operations to fully focus on the U.S. market.

Key Dates

Recommendation

While Nuwellis is making strategic progress in product development, market expansion (outpatient therapy, pediatrics), and focusing on the U.S. market, the financial performance for Q3 2025 shows significant challenges. Revenue declined year-over-year, gross margin compressed, and operating losses widened. The reported net income is misleading due to a non-cash gain. The company is burning cash and relies on capital raises (like the ATM facility). The strategic shifts are positive long-term, but the current financial metrics suggest a 'hold' position until there's clear evidence of improved revenue growth, gross margin recovery, and a path to profitability from core operations. Investors should monitor the execution of the U.S.-focused strategy and the impact of new product launches.

Keywords

Nuwellis, NUWE, Q3 2025, Financial Results, Cardio-renal, Medical Technology, Aquadex SmartFlow, Ultrafiltration, Fluid Management, Pediatrics, CRRT, Vivian System, Hospital Outpatient, CMS Code, Consumables, US Market Focus, Precision Fluid Management